Teva plans to divest its active-pharmaceutical ingredient business

Teva announced its intention to divest its active-pharmaceutical ingredient, or API, business, or “TAPI”. TAPI is a global leader in the small-molecule API industry, with approximately 4,300 employees worldwide. The intent to divest “TAPI” will allow Teva to maximize current and potential revenue streams, focusing on capital reallocation towards growth and innovation, and to better serve patients. The intended divestiture is expected to create additional value for Teva’s shareholders and other stakeholders by allowing Teva to better address distinct, growing markets with Teva’s leading product offerings. It will also allow the divested company to pursue new growth strategies, enabling it to maximize an array of opportunities in the $85 billion global API market. Teva expects the intended divestiture to be completed in the first half of 2025, subject to reaching a satisfactory agreement on transaction terms with a prospective purchaser, the successful satisfaction of closing conditions, and the approval of an agreed transaction by Teva’s Board of Directors.